Gilead Sciences Inc Price, Chart & Factor Exposure
Free Data & Analytics AccessNext earnings: Tue, Feb 9, 2027, after the market closes · estimates and history
Gilead Sciences Inc Forecast
Gilead Sciences Inc short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 37.4% a year, a typical one-standard-deviation range is 3,064–3,406 over a week, 2,885–3,585 over a month and 2,024–4,446 over a year. (Signals as of 5 Nov 2026.)
Gilead Sciences Inc Price Chart
Gilead Sciences Inc Factors
Research on Gilead Sciences Inc
Explore MacroFinance macro & markets research and analysis.
Gilead Sciences Inc Trading Strategies
28 backtested tactical asset allocation strategies hold EEM (emerging markets), the closest tradable exposure to Gilead Sciences Inc; 2 of them are invested now. Strategies currently invested are listed first.
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
Statistical Distribution of Returns
PlusHow Gilead Sciences Inc’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Gilead Sciences Inc (Mexico)
Gilead Sciences Inc is a listed security in Mexico. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on Gilead Sciences Inc
Frequently asked questions
What is Gilead Sciences Inc?
What is the latest Gilead Sciences Inc price?
Is Gilead Sciences Inc in an uptrend?
How volatile is Gilead Sciences Inc?
What factors affect Gilead Sciences Inc?
Which trading strategies trade Gilead Sciences Inc?
How are Gilead Sciences Inc returns analysed?
Where can I download free Gilead Sciences Inc historical data?
Free Gilead Sciences Inc historical data (last 10 years)
Browse or instantly download the last 10 years of Gilead Sciences Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.GILD.MX&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-19 | 3173.84 |
| 2026-11-18 | 3106.2 |
| 2026-11-17 | 3106.2 |
| 2026-11-13 | 3146.79 |
| 2026-11-12 | 3146.79 |
| 2026-11-11 | 3146.79 |
| 2026-11-10 | 3146.79 |
| 2026-11-09 | 3146.79 |
| 2026-11-06 | 3146.79 |
| 2026-11-05 | 3295 |
About this stock
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.